Maha Hussain

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi request reprint Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen
    Maha Hussain
    University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
    Clin Cancer Res 20:4218-27. 2014
  2. pmc Intermittent versus continuous androgen deprivation in prostate cancer
    Maha Hussain
    University of Michigan, Division of Hematology Oncology, 1500 E Medical Center Dr, 7314 CC, Ann Arbor, MI 48109 0946, USA
    N Engl J Med 368:1314-25. 2013
  3. ncbi request reprint Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial
    Maha H A Hussain
    University of Michigan, Ann Arbor, USA
    J Clin Oncol 25:2218-24. 2007
  4. ncbi request reprint A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer
    Maha Hussain
    Division of Hematology Oncology, Barbara Ann Karmanos Cancer Institute and Wayne State, University, Detroit, MI, USA
    Invest New Drugs 21:465-71. 2003
  5. pmc Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916
    Maha Hussain
    University of Michigan, Ann Arbor, MI 48109 0946, USA
    J Clin Oncol 27:2450-6. 2009
  6. ncbi request reprint Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells
    Yiwei Li
    Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, 715 Hudson Webber Cancer Research Center, 110 East Warren, Detroit, MI 48201, USA
    Mol Cancer Ther 4:389-98. 2005
  7. ncbi request reprint Lycopene and soy isoflavones in the treatment of prostate cancer
    Ulka Vaishampayan
    Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    Nutr Cancer 59:1-7. 2007
  8. ncbi request reprint Randomized clinical trial of a family intervention for prostate cancer patients and their spouses
    Laurel L Northouse
    School of Nursing, University of Michigan, Ann Arbor, Michigan 48109 5482, USA
    Cancer 110:2809-18. 2007
  9. ncbi request reprint Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma
    Petros D Grivas
    Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
    Cancer 120:692-701. 2014
  10. ncbi request reprint Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer
    Maha Hussain
    Division of Hematology Oncology, Wayne State University and Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA
    Urology 61:774-80. 2003

Detail Information

Publications70

  1. ncbi request reprint Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen
    Maha Hussain
    University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
    Clin Cancer Res 20:4218-27. 2014
    ..We investigated orteronel without steroids in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC; M0)...
  2. pmc Intermittent versus continuous androgen deprivation in prostate cancer
    Maha Hussain
    University of Michigan, Division of Hematology Oncology, 1500 E Medical Center Dr, 7314 CC, Ann Arbor, MI 48109 0946, USA
    N Engl J Med 368:1314-25. 2013
    ..Replacing androgens before progression of the disease is hypothesized to prolong androgen dependence...
  3. ncbi request reprint Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial
    Maha H A Hussain
    University of Michigan, Ann Arbor, USA
    J Clin Oncol 25:2218-24. 2007
    ....
  4. ncbi request reprint A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer
    Maha Hussain
    Division of Hematology Oncology, Barbara Ann Karmanos Cancer Institute and Wayne State, University, Detroit, MI, USA
    Invest New Drugs 21:465-71. 2003
    ..We conducted a phase II trial to evaluate the efficacy and toxicity of this agent in patients with advanced renal cell cancer (RCC)...
  5. pmc Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916
    Maha Hussain
    University of Michigan, Ann Arbor, MI 48109 0946, USA
    J Clin Oncol 27:2450-6. 2009
    ..Prostate-specific antigen progression (PSA-P) is an indicator of progression in hormone-sensitive (HS) and castration-resistant (CR) prostate cancer (PC). We evaluated different definitions of PSA-P as predictors of overall survival (OS)...
  6. ncbi request reprint Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells
    Yiwei Li
    Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, 715 Hudson Webber Cancer Research Center, 110 East Warren, Detroit, MI 48201, USA
    Mol Cancer Ther 4:389-98. 2005
    ..This information could be utilized for further mechanistic research and for devising optimized therapeutic strategies against prostate cancer...
  7. ncbi request reprint Lycopene and soy isoflavones in the treatment of prostate cancer
    Ulka Vaishampayan
    Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    Nutr Cancer 59:1-7. 2007
    ..Future studies are warranted to further investigate the efficacy of lycopene and soy isoflavones in prostate cancer as well as the mechanism of potential negative interaction between them...
  8. ncbi request reprint Randomized clinical trial of a family intervention for prostate cancer patients and their spouses
    Laurel L Northouse
    School of Nursing, University of Michigan, Ann Arbor, Michigan 48109 5482, USA
    Cancer 110:2809-18. 2007
    ....
  9. ncbi request reprint Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma
    Petros D Grivas
    Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
    Cancer 120:692-701. 2014
    ..Angiogenesis contributes to the progression of urothelial carcinoma (UC). In the current study, the authors investigated the role of maintenance sunitinib in patients with advanced UC...
  10. ncbi request reprint Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer
    Maha Hussain
    Division of Hematology Oncology, Wayne State University and Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, USA
    Urology 61:774-80. 2003
    ..To evaluate the efficacy and safety of neoadjuvant docetaxel and estramustine in patients with high-risk, newly diagnosed, prostate cancer...
  11. doi request reprint Update in systemic therapy of prostate cancer: improvement in quality and duration of life
    Ulka Vaishampayan
    4 HWCRC, 4100 John R Road, Detroit, MI 48201, USA
    Expert Rev Anticancer Ther 8:269-81. 2008
    ..This review attempts to summarize the risk profiling strategy in prostate cancer and the existing therapies in high-risk prostate cancer, including some of the novel agents under investigation...
  12. pmc Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line
    David A Davis
    Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
    BMC Cancer 6:22. 2006
    ....
  13. pmc A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone
    Kuei C Lee
    Department of Radiology, University of Michigan School of Medicine, Ann Arbor, MI 48109, USA
    Neoplasia 9:1003-11. 2007
    ..Thus, the fDM imaging biomarker may provide a quantifiable therapeutic endpoint to assess response in patients with metastatic bone cancer...
  14. ncbi request reprint A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder
    Petros D Grivas
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
    Urology 82:111-7. 2013
    ..To assess the activity of neoadjuvant nab-paclitaxel, carboplatin, gemcitabine (ACaG) followed by cystectomy in patients with muscle-invasive urothelial carcinoma of the bladder...
  15. ncbi request reprint In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer
    Sanjeev Banerjee
    Department of Pathology, Barbara Ann Karmanos Cancer Institute, 4160 John R Street, Detroit, MI 48201, USA
    Cancer Res 67:3818-26. 2007
    ..Most importantly, the antitumor activity was associated with the down-regulation of molecular markers in tumor tissues that were similar to those observed in vitro...
  16. pmc Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder
    David C Smith
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan School of Medicine, University of Michigan, Ann Arbor, Michigan, USA
    J Urol 180:2384-8; discussion 2388. 2008
    ..This 2-arm phase II multicenter trial was designed to assess the efficacy and toxicity of neoadjuvant paclitaxel, gemcitabine and carboplatin in patients with invasive bladder cancer...
  17. pmc Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer
    Judah Friedman
    Division of Hematology and Oncology, Department of Medicine, University of Michigan School of Medicine and University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0946, USA
    J Urol 179:911-5; discussion 915-6. 2008
    ..We assessed activity and safety of neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer...
  18. ncbi request reprint Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)
    Maha Hussain
    University of Michigan, Ann Arbor, MI, USA
    J Clin Oncol 24:3984-90. 2006
    ..To establish whether absolute prostate-specific antigen (PSA) value after androgen deprivation (AD) is prognostic in metastatic (D2) prostate cancer (PCa)...
  19. ncbi request reprint Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer
    Yiwei Li
    Department of Pathology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Cancer Res 66:4816-25. 2006
    ..From these results, we conclude that genistein could be a promising nontoxic agent to improve the treatment outcome of metastatic prostate cancer with docetaxel...
  20. pmc Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and Universi
    Deborah Bradley
    Department of Medicine and Urology, University of Michigan, Ann Arbor, Michigan, USA
    Cancer 115:5541-9. 2009
    ..This phase 2 trial was designed to evaluate the efficacy of vorinostat in chemotherapy-pretreated patients with metastatic castration-resistant prostate cancer...
  21. ncbi request reprint Gene expression profiling reveals novel targets of estramustine phosphate in prostate cancer cells
    Xin Hong
    Department of Pathology, Wayne State University School of Medicine, 9374 Scott Hall, 540 East Canfield, Detroit, MI 48201, USA
    Cancer Lett 209:187-95. 2004
    ..EMP-induced regulation of these genes may be further exploited for devising therapeutic strategies for prostate cancer...
  22. ncbi request reprint Promising novel cytotoxic agents and combinations in metastatic prostate cancer
    Deborah A Bradley
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan, Ann Arbor, MI 48109 0946, USA
    Cancer J 14:15-9. 2008
    ..This result led to an expansion in research in this area with several ongoing trials evaluating docetaxel-based combinations and new cytotoxic agents...
  23. pmc Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium
    Ajjai Alva
    University of Michigan Comprehensive Cancer Center, 7314 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109 5946, USA
    Invest New Drugs 30:749-57. 2012
    ..We conducted a phase II study of cilengitide, a selective antagonist of α(v)β(3) and α(v)β(5) integrins, in non-metastatic castration resistant prostate cancer with rising PSA...
  24. ncbi request reprint Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111
    Maha Hussain
    University of Michigan Comprehensive Cancer Center, Ann Arbor, USA
    J Clin Oncol 23:8724-9. 2005
    ..The epothilones are a new class of tubulin-polymerizing agents with activity in taxane-sensitive and resistant tumor models. We evaluated ixabepilone (BMS-247550) in patients with metastatic hormone-refractory prostate cancer (HRPC)...
  25. doi request reprint Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, Weill Cornell Medical College, 525 East 68th Street, 3rd Floor, New York, NY 10065, USA
    Invest New Drugs 30:249-57. 2012
    ..We conducted a phase I trial to determine the dose level of vorinostat plus docetaxel that would result in dose-limiting toxicity (DLT) in ≤30% of patients...
  26. ncbi request reprint Phase II trial of estramustine and etoposide in androgen-sensitive metastatic prostate carcinoma
    Ulka Vaishampayan
    Division of Hematology Oncology, Barbara Ann Karmanos Cancer Institute and Wayne State University, Detroit, Michiga, USA
    Am J Clin Oncol 27:550-4. 2004
    ..Hence, a phase II trial was conducted to evaluate the efficacy and toxicity of estramustine and etoposide in hormone-sensitive metastatic prostate cancer...
  27. ncbi request reprint Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design
    Kathleen W Beekman
    Genitourinary Oncology Service, Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, 48109, USA
    Clin Genitourin Cancer 4:299-302. 2006
    ....
  28. pmc Gene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cells
    Yiwei Li
    Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
    BMC Cancer 5:7. 2005
    ..However, the molecular mechanisms of action of Taxotere and Capecitabine have not been fully elucidated in prostate cancer...
  29. ncbi request reprint Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial
    David C Smith
    University of Michigan, Ann Arbor, MI, USA
    J Clin Oncol 31:412-9. 2013
    ..We evaluated the activity of cabozantinib in patients with castration-resistant prostate cancer (CRPC) in a phase II randomized discontinuation trial with an expansion cohort...
  30. ncbi request reprint Management of patients with muscle-invasive and metastatic bladder cancer
    N Lynn Henry
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 0946, USA
    Oncology (Williston Park) 19:1333-42; discussion 1342, 1347, 1350 passim. 2005
    ..Progress in the treatment of this disease is dependent on supporting ongoing and future clinical trials...
  31. ncbi request reprint An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer
    Ulka Vaishampayan
    Division of Hematology Oncology, Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, Detroit, Michigan, USA
    Urology 60:1050-4. 2002
    ..The efficacy of weekly high-dose paclitaxel in androgen-independent prostate carcinoma and its cytotoxic synergy with estramustine led to the evaluation of a weekly schedule of paclitaxel and estramustine in this Phase II trial...
  32. ncbi request reprint Living with prostate cancer: patients' and spouses' psychosocial status and quality of life
    Laurel L Northouse
    School of Nursing and the Division of Hematology Oncology, Department of Urology, University of Michigan, Ann Arbor 48109 0482, USA
    J Clin Oncol 25:4171-7. 2007
    ..This study assessed patients' and spouses' quality of life, appraisal of illness, resources, symptoms, and risk for distress across three phases of prostate cancer: newly diagnosed, biochemical recurrence, and advanced...
  33. ncbi request reprint Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design
    Deborah A Bradley
    University of Michigan, Ann Arbor, MI 48109 0946, USA
    Clin Genitourin Cancer 5:460-3. 2007
    ..The specific hypothesis of this trial is that sunitinib will decrease progression rates in patients with advanced urothelial cancer who have obtained stable disease or better after standard chemotherapy...
  34. pmc Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer
    Petros D Grivas
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, United States of America Translational Oncology Program, University of Michigan, Ann Arbor, Michigan, United States of America University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, United States of America
    Mol Med 19:367-76. 2013
    ..Further investigation of dacomitinib in the preclinical and clinical trial settings is being pursued. ..
  35. pmc Randomized clinical trial of a brief and extensive dyadic intervention for advanced cancer patients and their family caregivers
    Laurel L Northouse
    School of Nursing, University of Michigan, Ann Arbor, MI 48109, USA
    Psychooncology 22:555-63. 2013
    ....
  36. ncbi request reprint Novel gemcitabine-containing triplets in the management of urothelial cancer
    Maha Hussain
    Division of Hematology Oncology, Wayne State University and the Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
    Semin Oncol 29:20-4. 2002
    ..The role of gemcitabine-based multiagent combinations compared with standard therapy awaits evaluation in prospectively randomized trials...
  37. ncbi request reprint Clinical trials in metastatic prostate cancer--has there been real progress in the past decade?
    Manish S Bhandari
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
    Eur J Cancer 41:941-53. 2005
    ..Key to progress in the therapy of this fatal disease is the commitment and timely enrolment of prostate cancer patients in clinical trials...
  38. ncbi request reprint Soy isoflavones in the treatment of prostate cancer
    Maha Hussain
    Division of Hematology and Oncology, Wayne State University, Detroit, MI 48201, USA
    Nutr Cancer 47:111-7. 2003
    ..00002) and from 0.11 to 0.51 microM (P = 0.00001), respectively. No significant changes were observed in serum levels of testosterone, IGF-1, IGFBP-3, or 5-OHmdU. These data suggest that soy isoflavones may benefit some patients with Pca...
  39. ncbi request reprint Phase II trial of fenretinide in advanced renal carcinoma
    Ulka Vaishampayan
    Division of Oncology, Wayne State University Karmanos Cancer Institute, Detroit, MI, USA
    Invest New Drugs 23:179-85. 2005
    ..Fenretinide, a synthetic form of retinoid, induced apoptosis even in chemotherapy resistant cell lines. A phase II study was hence conducted to evaluate toxicity and efficacy of fenretinide in metastatic renal cancer...
  40. ncbi request reprint Epothilones and the next generation of phase III trials for prostate cancer
    Manish S Bhandari
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
    BJU Int 96:296-302. 2005
  41. pmc Regulation of microtubule, apoptosis, and cell cycle-related genes by taxotere in prostate cancer cells analyzed by microarray
    Yiwei Li
    Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Neoplasia 6:158-67. 2004
    ..Nevertheless, our results could be further exploited for devising strategies to optimize therapeutic effects of Taxotere for the treatment of prostate cancer...
  42. ncbi request reprint New molecular targets and novel agents in the treatment of advanced urothelial cancer
    Kathleen W Beekman
    Genitourinary Oncology Service, Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
    Semin Oncol 34:154-64. 2007
    ..The evaluation of new targets and new agents in the midst of limited patient, logistical, and financial resources will be one of the more difficult challenges for investigators over the next several years...
  43. ncbi request reprint Should intermittent androgen deprivation be used in routine clinical practice?
    Manish S Bhandari
    Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA
    J Clin Oncol 23:8212-8. 2005
    ..We also discuss special considerations for using IAD outside the context of a clinical trial...
  44. ncbi request reprint Non-castrate metastatic prostate cancer: have the treatment options changed?
    Phillip L Palmbos
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan, Ann Arbor, MI 48109 5946, USA
    Semin Oncol 40:337-46. 2013
    ..In this review, we outline the biologic drivers of NCPC, review current standard therapy available for NCPC, and discuss the evolving role of new therapeutics in metastatic disease. ..
  45. doi request reprint The changing natural history of metastatic prostate cancer
    Ajjai Alva
    Division of Hematology Oncology, Department of Internal Medicine, and University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA
    Cancer J 19:19-24. 2013
    ....
  46. ncbi request reprint Outcomes for radiation therapy after radical prostatectomy for prostate cancer: what really matters?
    James E Montie
    The University of Michigan Medical Center, Ann Arbor, MI, USA
    BJU Int 100:485-6. 2007
  47. ncbi request reprint Molecular biology of transitional cell carcinoma
    Sana Al-Sukhun
    Department of Internal Medicine, Division of Hematology Oncology, Wayne State University School of Medicine and The Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
    Crit Rev Oncol Hematol 47:181-93. 2003
    ..This review will highlight these important advances and emphasize the ways in which molecular biology is likely to affect the development of future therapies...
  48. pmc Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer
    J Chad Brenner
    Michigan Center for Translational Pathology, University of Michigan, 1400 E Medical Center Drive, 5316 CCGC, Ann Arbor, MI 48109, USA
    Cancer Cell 19:664-78. 2011
    ..Finally, overexpression of the TMPRSS2:ERG fusion induces DNA damage, which is potentiated by PARP1 inhibition in a manner similar to that of BRCA1/2 deficiency...
  49. doi request reprint Hormonal approaches in prostate cancer: application in the contemporary prostate cancer patient
    Kathleen W Beekman
    Genitourinary Oncology Service, Department of Medicine, Division of Hematology Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI 48109, USA
    Urol Oncol 26:415-9. 2008
    ..With the onset of routine PSA testing and the subsequent stage migration that has occurred in men presenting with prostate cancer, the question of when to initiate hormonal therapy has become ever more controversial...
  50. doi request reprint Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma
    Ajjai Alva
    University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
    Invest New Drugs 32:188-94. 2014
    ..We assessed the efficacy of nab-paclitaxel in combination with carboplatin and gemcitabine as first line therapy in advanced urothelial cancer...
  51. ncbi request reprint Chemotherapy for prostate cancer: implementing early systemic therapy to improve outcomes
    Gary R Macvicar
    Division of Hematology Oncology, Northwestern University, Chicago, IL 60611, USA
    Cancer Chemother Pharmacol 56:69-77. 2005
    ....
  52. ncbi request reprint Targeted approaches for the management of metastatic prostate cancer
    Kathleen W Beekman
    Genitourinary Oncology Service, Department of Medicine, Division of Hematology Oncology, University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, C 409 0843 MIB, Ann Arbor, MI, 48109 0843, USA
    Curr Oncol Rep 8:206-12. 2006
    ..This review is intended to highlight these potential targets and several of the agents that are under development in the treatment of prostate cancer...
  53. pmc Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancer
    Petros D Grivas
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan, Ann Arbor, MI 48109, USA
    Crit Rev Oncol Hematol 85:82-93. 2013
    ..This review summarizes the current data on the role of several candidate biomarkers that have been evaluated in the advanced/metastatic disease setting...
  54. ncbi request reprint Couples' experiences with prostate cancer: focus group research
    Janet Harden
    College of Nursing, Wayne State University, Detroit, MI, USA
    Oncol Nurs Forum 29:701-9. 2002
    ....
  55. ncbi request reprint The evolving role of systemic therapy in high risk prostate cancer: strategies for cure in the 21st century
    Ulka Vaishampayan
    Division of Hematology Oncology, Department of Internal Medicine, Wayne State University School of Medicine Barbara Ann Karmanos Cancer Institute, 5 Hudson, Harper Hospital, Detroit, MI 48201, USA
    Crit Rev Oncol Hematol 42:179-88. 2002
    ..Novel avenues of therapy such as tyrosine kinase inhibitors, gene therapy and angiogenesis inhibitors incorporated in a multimodality treatment strategy are likely to impact the course of this disease in the future...
  56. ncbi request reprint Bone directed therapies for prostate cancer
    Deborah A Bradley
    Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA
    J Urol 178:S42-8. 2007
    ..We provide an overview of recent advances in understanding bone biology, and bone targeted therapy research and development...
  57. ncbi request reprint Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer
    Alon Z Weizer
    Department of Urology, University of Michigan, Ann Arbor, Michigan 48109, USA
    J Urol 177:1287-93. 2007
    ..This study examines patterns of treatment in this population and evaluates the impact of these factors on overall survival in a contemporary population...
  58. ncbi request reprint Survival analysis of distant prostate cancer by decade (1973-1997) in the Detroit Metropolitan Surveillance, Epidemiology and End Results (SEER) Program registry: has outcome improved? (United States)
    Jill S Barnholtz-Sloan
    Division of Hematology Oncology, Department of Internal Medicine, Wayne State University School of Medicine and The Barbara Ann Karmanos Cancer Institute, Detroit, Michigan 48201, USA
    Cancer Causes Control 14:681-5. 2003
    ..The purpose of this study is to examine differences in survival after diagnosis with distant stage prostate cancer by decade of diagnosis...
  59. ncbi request reprint Current understanding of the biology of advanced bladder cancer
    Sana Al-Sukhun
    Division of Hematology Oncology, Karmanos Cancer Institute and Wayne State University School of Medicine, Detroit, Michigan 48109, USA
    Cancer 97:2064-75. 2003
    ..It is likely that in the new millennium, real breakthroughs in the identification and therapy of high-risk, poor-prognosis patients will come from an integration of molecular modalities in the clinical application...
  60. doi request reprint Intermittent androgen deprivation therapy in advanced prostate cancer
    Ajjai Alva
    University of Michigan Comprehensive Cancer Center, 1500 East Medical Center Drive, Room 7314, Ann Arbor, MI, 48109 5946, USA
    Curr Treat Options Oncol 15:127-36. 2014
    ..If validated, they would represent a long overdue paradigm shift in advanced hormone sensitive prostate cancer management...
  61. ncbi request reprint Unusual hematologic malignancies. Case 2. Mediastinal germ cell tumor, malignant histiocytosis, and acute leukemia
    Ulka Vaishampayan
    Wayne State University, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA
    J Clin Oncol 20:3739-42. 2002
  62. ncbi request reprint Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916
    R Bruce Montgomery
    University of Washington and Southwest Oncology Group Statistical Center, Seattle, Washington, USA
    J Urol 178:1946-51; discussion 1951. 2007
    ..We evaluated the effect of body mass index on prostate specific antigen response, and progression-free and overall survival in men with androgen dependent or androgen independent metastatic prostate cancer...
  63. ncbi request reprint The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894
    Tomasz M Beer
    Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon, USA
    Cancer 107:489-96. 2006
    ....
  64. ncbi request reprint Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma
    Scot Ebbinghaus
    Arizona Cancer Center, Tucson, AZ, USA
    Clin Cancer Res 13:6689-95. 2007
    ..ABT-510 is an angiogenesis inhibitor that mimics the antiangiogenic properties of thrombospondin-1. This study was designed to assess the safety and efficacy of ABT-510 in patients with advanced renal cell carcinoma...
  65. ncbi request reprint Ten-year survival in patients with metastatic prostate cancer
    Catherine M Tangen
    The Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Clin Prostate Cancer 2:41-5. 2003
    ..Although statistically significant baseline characteristics were identified in this clinical trial, they did not accurately predict the survival interval to which a patient belonged...
  66. ncbi request reprint Castration resistant, taxane naïve metastatic prostate cancer: current clinical approaches and future directions
    Gretchen A Gignac
    Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 178:S30-5. 2007
    ..We focused on the current management and novel investigational strategies for the chemonaïve patient population with castration resistant metastatic disease...
  67. pmc Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group
    Howard I Scher
    Genitourinary Oncology Service, Department of Medicine, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    J Clin Oncol 26:1148-59. 2008
    ..To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone...
  68. pmc A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer
    Richard T Lee
    Department of Medicine, Section of Hematology Oncology, The University of Chicago, IL 60637, USA
    Clin Genitourin Cancer 6:21-4. 2008
    ..SB-715992 is a new agent that inhibits the function of a mitotic kinesin known as kinesin spindle protein and leads to cell death...
  69. ncbi request reprint Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer
    David J Vaughn
    University of Pennsylvania Cancer Center, Philadelphia, PA 19104, USA
    J Clin Oncol 20:937-40. 2002
    ..We evaluated the efficacy and toxicity of weekly paclitaxel in patients with previously treated advanced urothelial cancer...
  70. ncbi request reprint Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733
    Celestia S Higano
    Department of Medicine, Division of Oncology, University of Washington, Seattle, Washington, USA
    Cancer 112:2181-7. 2008
    ..Many patients with invasive urothelial cell cancer are poor candidates for cisplatin-based chemotherapy, and many are high risk for cystectomy. Southwest Oncology Group Trial 8733 was designed to address treatment for such patients...